BRPI0520812A2 - método para preparar um composto de quinolina 4-substituìda, e, composto - Google Patents

método para preparar um composto de quinolina 4-substituìda, e, composto

Info

Publication number
BRPI0520812A2
BRPI0520812A2 BRPI0520812-2A BRPI0520812A BRPI0520812A2 BR PI0520812 A2 BRPI0520812 A2 BR PI0520812A2 BR PI0520812 A BRPI0520812 A BR PI0520812A BR PI0520812 A2 BRPI0520812 A2 BR PI0520812A2
Authority
BR
Brazil
Prior art keywords
preparing
quinoline compound
substituted quinoline
compound
quinoline
Prior art date
Application number
BRPI0520812-2A
Other languages
English (en)
Inventor
Youchu Wang
Chew Warren
Maria Papamichelakis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0520812A2 publication Critical patent/BRPI0520812A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MéTODO PARA PREPARAR UM COMPOSTO DE QUINOLINA 4-SUBSTITUìDA, E, COMPOSTO. Esta invenção é direcionada a métodos de preparar compostos de quinolina 4-substituida como intermediários na preparação de inibidores de tirosina quinase de receptor e compostos intermediários usados nos seus métodos, em que o composto de quinolina tem a fórmula geral (I): e em que substituições em LG",PG, A, G, R~ 1~ e R~ 4~ são especificadas no relatório descritivo.
BRPI0520812-2A 2004-01-16 2005-01-14 método para preparar um composto de quinolina 4-substituìda, e, composto BRPI0520812A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53732904P 2004-01-16 2004-01-16
PCT/US2005/001384 WO2005070890A2 (en) 2004-01-16 2005-01-14 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof

Publications (1)

Publication Number Publication Date
BRPI0520812A2 true BRPI0520812A2 (pt) 2009-10-06

Family

ID=34807094

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520812-2A BRPI0520812A2 (pt) 2004-01-16 2005-01-14 método para preparar um composto de quinolina 4-substituìda, e, composto

Country Status (20)

Country Link
US (2) US7432377B2 (pt)
EP (1) EP1711467A2 (pt)
KR (1) KR20060123545A (pt)
CN (1) CN1930128A (pt)
AR (1) AR047424A1 (pt)
AU (1) AU2005206541A1 (pt)
BR (1) BRPI0520812A2 (pt)
CA (1) CA2553729A1 (pt)
CR (1) CR8530A (pt)
EC (1) ECSP066773A (pt)
GT (1) GT200500008A (pt)
MY (1) MY136959A (pt)
NO (1) NO20063501L (pt)
PA (1) PA8621501A1 (pt)
PE (1) PE20050896A1 (pt)
RU (1) RU2006127414A (pt)
SG (1) SG149817A1 (pt)
TW (1) TW200526219A (pt)
UA (1) UA85698C2 (pt)
WO (1) WO2005070890A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553729A1 (en) * 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
CN101180269A (zh) * 2005-05-25 2008-05-14 惠氏公司 制备3-氰基-喹啉的方法和由其制得的中间体
BRPI0610147A2 (pt) * 2005-05-25 2010-06-01 Wyeth Corp método para preparar e sintetizar 3-cianoquinolinas substituìdas e 4-amino-3-cianoquinolinas
TW200808728A (en) * 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
EP2300013B2 (en) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
SG10201508958WA (en) 2010-11-01 2015-11-27 Celgene Avilomics Res Inc Heterocyclic Compounds And Uses Thereof
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
JP6317319B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN106535733A (zh) * 2014-09-01 2017-03-22 伊莱克斯电器股份公司 支撑组件
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105503720B (zh) * 2015-12-31 2018-07-03 重庆威鹏药业有限公司 来那替尼中间体的制备方法
CN107501175A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
CN107417612A (zh) * 2017-07-25 2017-12-01 广州大学 一种喹啉衍生物的合成方法
CN107501174A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
KR102713340B1 (ko) * 2022-11-08 2024-10-02 경희대학교 산학협력단 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
AU742739B2 (en) 1997-05-28 2002-01-10 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU6159499A (en) 1998-09-29 2000-04-17 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7009053B2 (en) * 2002-04-30 2006-03-07 Yungjin Pharmaceuticals Co., Ltd. Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
CA2553729A1 (en) 2004-01-16 2005-08-04 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity

Also Published As

Publication number Publication date
US20090030197A1 (en) 2009-01-29
SG149817A1 (en) 2009-02-27
ECSP066773A (es) 2006-11-16
AR047424A1 (es) 2006-01-18
MY136959A (en) 2008-12-31
CR8530A (es) 2008-09-23
TW200526219A (en) 2005-08-16
PE20050896A1 (es) 2005-11-14
EP1711467A2 (en) 2006-10-18
PA8621501A1 (es) 2005-08-10
CA2553729A1 (en) 2005-08-04
WO2005070890A3 (en) 2005-11-03
NO20063501L (no) 2006-09-28
GT200500008A (es) 2005-08-16
RU2006127414A (ru) 2008-02-27
KR20060123545A (ko) 2006-12-01
UA85698C2 (ru) 2009-02-25
CN1930128A (zh) 2007-03-14
US7432377B2 (en) 2008-10-07
WO2005070890A2 (en) 2005-08-04
AU2005206541A1 (en) 2005-08-04
US20050159446A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
CO6270363A2 (es) Novedosos compuestos erivados aromaticos como inhibidores de c-fms kinase
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
BRPI0410720A (pt) quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
GEP20115171B (en) Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
BRPI0509761A (pt) compostos de quinolinona-carboxamida como agonista de receptor de 5-ht4
BRPI0513475A (pt) derivados quinazolin-4-il-piperidina e cinolin-4-il-piperidina como inibidores de pde10 no tratamento de distúrbios do snc
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
BRPI0409002A (pt) pirazóis 1,3,4-substituìdos para uso como antagonistas receptores 5h-t no tratamento de psicoses e distúrbios neurológicos
NO20081621L (no) Tetrahydrokinoliner, syntese og intermediater
NO20091817L (no) Kinase inhibitorer
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
GT200400143A (es) Compuestos
BRPI0411308A8 (pt) Composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BRPI0511999A (pt) compostos como antagonistas de ccr5
BRPI0414494A (pt) compostos, composições farmacêuticas, e, uso de um composto
MX2007007446A (es) Procesos para la produccion de 4-aminoquinazolinas.
GT200500241A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2160 DE 29/05/2012.